Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Respiratory Infectious Disease Diagnostics Market by Test Type (Mechanical tests, Imaging Tests, In Vitro Diagnostics (IVD) Tests), by Disease Type (Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, Tuberculosis, Other Diseases) and by End User (Hospitals, Physician Offices, Clinical Laboratories, Other End Users): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04149

Pages: NA

Charts: NA

Tables: NA

According to the World Health Organization (WHO), respiratory infectious diseases are the third leading cause of death and result in over all three million deaths per year across the world. These diseases include pneumonia, bronchitis, sinus infections, laryngitis, and others. During the diagnostics of respiratory diseases, doctor mainly focuses on breathing issues and X-ray or CT scan to check the lower respiratory tract. Sometimes, fluid and inflammation in the lungs is also checked.

Rise in prevalence of respiratory diseases, growth in adoption of advanced molecular techniques, increase in geriatric population, and initiatives taken by government and non-profile organization to minimize the incidence of infectious diseases drive the market. However, factors such as lack of awareness about diagnostic solution and high cost of laboratory testing restrain the market growth. Further, development of cost effective tools for the infectious disease diagnosis and growth in concern about the disease in low-income countries provide lucrative opportunities for the market growth during the forecast period.

The respiratory infectious disease diagnostics market is segmented based on test type, disease type, end user, and region. Based on test type, it is categorized into mechanical tests, imaging tests, and in vitro diagnostics (IVD) tests. Mechanical tests are further segmented into spirometry, peak flow test, blood gas test, pulmonary function test, and obstructive sleep apnea (OSA) diagnostic test. In vitro diagnostics (IVD) tests are further divided into point-of-care (POC) test, molecular diagnostic test, and other tests. On the basis of disease type, the market is classified into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. On the basis of end user, the market is divided into hospital, clinical laboratories, physician offices, and other end users. By geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the global respiratory infectious disease diagnostics market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the global respiratory infectious disease diagnostics market.

 Key Market Segments

  • By Test Type
    • Mechanical tests
    • Imaging Tests
    • In Vitro Diagnostics (IVD) Tests
  • By Disease Type
    • Asthma
    • Chronic Obstructive Pulmonary Disease
    • Lung Cancer
    • Tuberculosis
    • Other Diseases
  • By End User
    • Hospitals
    • Physician Offices
    • Clinical Laboratories
    • Other End Users
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • NIHON KOHDEN CORPORATION,
  • COSMED
  • Thermo Fisher Scientific Inc.
  • Alere, Inc.
  • F. Hoffmann-La Roche AG.
  • Smiths Group plc
  • Cardinal Health
  • Abbott Laboratories
  • Koninklijke Philips N.V.
  • Becton, Dickinson and Company

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TEST TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Test Type

    • 4.2. Mechanical Tests

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Imaging Tests

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. In Vitro Diagnostics (IVD) Tests

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Type

    • 5.2. Asthma

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Chronic Obstructive Pulmonary Disease

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Lung Cancer

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Tuberculosis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Other Diseases

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Physician Offices

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Clinical Laboratories

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Other End Users

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Test Type

      • 7.2.3. Market Size and Forecast, By Disease Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Respiratory Infectious Disease Diagnostics Market

        • 7.2.6.1. Market Size and Forecast, By Test Type
        • 7.2.6.2. Market Size and Forecast, By Disease Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Respiratory Infectious Disease Diagnostics Market

        • 7.2.7.1. Market Size and Forecast, By Test Type
        • 7.2.7.2. Market Size and Forecast, By Disease Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Respiratory Infectious Disease Diagnostics Market

        • 7.2.8.1. Market Size and Forecast, By Test Type
        • 7.2.8.2. Market Size and Forecast, By Disease Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Test Type

      • 7.3.3. Market Size and Forecast, By Disease Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Respiratory Infectious Disease Diagnostics Market

        • 7.3.6.1. Market Size and Forecast, By Test Type
        • 7.3.6.2. Market Size and Forecast, By Disease Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Respiratory Infectious Disease Diagnostics Market

        • 7.3.7.1. Market Size and Forecast, By Test Type
        • 7.3.7.2. Market Size and Forecast, By Disease Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Respiratory Infectious Disease Diagnostics Market

        • 7.3.8.1. Market Size and Forecast, By Test Type
        • 7.3.8.2. Market Size and Forecast, By Disease Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Respiratory Infectious Disease Diagnostics Market

        • 7.3.9.1. Market Size and Forecast, By Test Type
        • 7.3.9.2. Market Size and Forecast, By Disease Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Respiratory Infectious Disease Diagnostics Market

        • 7.3.10.1. Market Size and Forecast, By Test Type
        • 7.3.10.2. Market Size and Forecast, By Disease Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Respiratory Infectious Disease Diagnostics Market

        • 7.3.11.1. Market Size and Forecast, By Test Type
        • 7.3.11.2. Market Size and Forecast, By Disease Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Respiratory Infectious Disease Diagnostics Market

        • 7.3.12.1. Market Size and Forecast, By Test Type
        • 7.3.12.2. Market Size and Forecast, By Disease Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Test Type

      • 7.4.3. Market Size and Forecast, By Disease Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Respiratory Infectious Disease Diagnostics Market

        • 7.4.6.1. Market Size and Forecast, By Test Type
        • 7.4.6.2. Market Size and Forecast, By Disease Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Respiratory Infectious Disease Diagnostics Market

        • 7.4.7.1. Market Size and Forecast, By Test Type
        • 7.4.7.2. Market Size and Forecast, By Disease Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Respiratory Infectious Disease Diagnostics Market

        • 7.4.8.1. Market Size and Forecast, By Test Type
        • 7.4.8.2. Market Size and Forecast, By Disease Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Respiratory Infectious Disease Diagnostics Market

        • 7.4.9.1. Market Size and Forecast, By Test Type
        • 7.4.9.2. Market Size and Forecast, By Disease Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Respiratory Infectious Disease Diagnostics Market

        • 7.4.10.1. Market Size and Forecast, By Test Type
        • 7.4.10.2. Market Size and Forecast, By Disease Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Respiratory Infectious Disease Diagnostics Market

        • 7.4.11.1. Market Size and Forecast, By Test Type
        • 7.4.11.2. Market Size and Forecast, By Disease Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Respiratory Infectious Disease Diagnostics Market

        • 7.4.12.1. Market Size and Forecast, By Test Type
        • 7.4.12.2. Market Size and Forecast, By Disease Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Respiratory Infectious Disease Diagnostics Market

        • 7.4.13.1. Market Size and Forecast, By Test Type
        • 7.4.13.2. Market Size and Forecast, By Disease Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Respiratory Infectious Disease Diagnostics Market

        • 7.4.14.1. Market Size and Forecast, By Test Type
        • 7.4.14.2. Market Size and Forecast, By Disease Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Test Type

      • 7.5.3. Market Size and Forecast, By Disease Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Respiratory Infectious Disease Diagnostics Market

        • 7.5.6.1. Market Size and Forecast, By Test Type
        • 7.5.6.2. Market Size and Forecast, By Disease Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Respiratory Infectious Disease Diagnostics Market

        • 7.5.7.1. Market Size and Forecast, By Test Type
        • 7.5.7.2. Market Size and Forecast, By Disease Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Respiratory Infectious Disease Diagnostics Market

        • 7.5.8.1. Market Size and Forecast, By Test Type
        • 7.5.8.2. Market Size and Forecast, By Disease Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Respiratory Infectious Disease Diagnostics Market

        • 7.5.9.1. Market Size and Forecast, By Test Type
        • 7.5.9.2. Market Size and Forecast, By Disease Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Respiratory Infectious Disease Diagnostics Market

        • 7.5.10.1. Market Size and Forecast, By Test Type
        • 7.5.10.2. Market Size and Forecast, By Disease Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Respiratory Infectious Disease Diagnostics Market

        • 7.5.11.1. Market Size and Forecast, By Test Type
        • 7.5.11.2. Market Size and Forecast, By Disease Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott Laboratories

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Thermo Fisher Scientific Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Alere, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Koninklijke Philips N.V.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Cardinal Health

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. COSMED

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Smiths Group Plc

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. NIHON KOHDEN CORPORATION,

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Becton, Dickinson And Company

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. F. Hoffmann-La Roche AG.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMAGING TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IN VITRO DIAGNOSTICS (IVD) TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ASTHMA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. U.S. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. CANADA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 26. CANADA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. ITALY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 42. ITALY RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. UK RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 47. UK RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 48. UK RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. CHINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 61. CHINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. INDIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 67. INDIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. UAE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 100. UAE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 101. UAE RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY TEST TYPE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 109. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 110. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 111. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 112. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 114. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 115. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 116. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 117. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ALERE, INC.: KEY EXECUTIVES
  • TABLE 119. ALERE, INC.: COMPANY SNAPSHOT
  • TABLE 120. ALERE, INC.: OPERATING SEGMENTS
  • TABLE 121. ALERE, INC.: PRODUCT PORTFOLIO
  • TABLE 122. ALERE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 124. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 125. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 126. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 127. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 129. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 130. CARDINAL HEALTH: OPERATING SEGMENTS
  • TABLE 131. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 132. CARDINAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. COSMED: KEY EXECUTIVES
  • TABLE 134. COSMED: COMPANY SNAPSHOT
  • TABLE 135. COSMED: OPERATING SEGMENTS
  • TABLE 136. COSMED: PRODUCT PORTFOLIO
  • TABLE 137. COSMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. SMITHS GROUP PLC: KEY EXECUTIVES
  • TABLE 139. SMITHS GROUP PLC: COMPANY SNAPSHOT
  • TABLE 140. SMITHS GROUP PLC: OPERATING SEGMENTS
  • TABLE 141. SMITHS GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 142. SMITHS GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. NIHON KOHDEN CORPORATION,: KEY EXECUTIVES
  • TABLE 144. NIHON KOHDEN CORPORATION,: COMPANY SNAPSHOT
  • TABLE 145. NIHON KOHDEN CORPORATION,: OPERATING SEGMENTS
  • TABLE 146. NIHON KOHDEN CORPORATION,: PRODUCT PORTFOLIO
  • TABLE 147. NIHON KOHDEN CORPORATION,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 149. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 150. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 151. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 152. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. F. HOFFMANN-LA ROCHE AG.: KEY EXECUTIVES
  • TABLE 154. F. HOFFMANN-LA ROCHE AG.: COMPANY SNAPSHOT
  • TABLE 155. F. HOFFMANN-LA ROCHE AG.: OPERATING SEGMENTS
  • TABLE 156. F. HOFFMANN-LA ROCHE AG.: PRODUCT PORTFOLIO
  • TABLE 157. F. HOFFMANN-LA ROCHE AG.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • FIGURE 3. SEGMENTATION RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • FIGURE 11. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY TEST TYPE
  • FIGURE 12. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IN VITRO DIAGNOSTICS (IVD) TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY DISEASE TYPE
  • FIGURE 16. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PHYSICIAN OFFICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: RESPIRATORY INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ALERE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ALERE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ALERE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. KONINKLIJKE PHILIPS N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. CARDINAL HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. CARDINAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. CARDINAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. COSMED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. COSMED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. COSMED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. SMITHS GROUP PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. SMITHS GROUP PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. SMITHS GROUP PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. NIHON KOHDEN CORPORATION,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. NIHON KOHDEN CORPORATION,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. NIHON KOHDEN CORPORATION,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. BECTON, DICKINSON AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. F. HOFFMANN-LA ROCHE AG.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. F. HOFFMANN-LA ROCHE AG.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. F. HOFFMANN-LA ROCHE AG.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Respiratory Infectious Disease Diagnostics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved